当前位置: X-MOL 学术CA: Cancer J. Clin. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Hodgkin lymphoma: A review and update on recent progress
CA: A Cancer Journal for Clinicians ( IF 254.7 ) Pub Date : 2017-12-01 , DOI: 10.3322/caac.21438
Satish Shanbhag 1 , Richard F. Ambinder 2
Affiliation  

Hodgkin lymphoma (HL) is a unique hematopoietic neoplasm characterized by cancerous Reed‐Sternberg cells in an inflammatory background. Patients are commonly diagnosed with HL in their 20s and 30s, and they present with supradiaphragmatic lymphadenopathy, often with systemic B symptoms. Even in advanced‐stage disease, HL is highly curable with combination chemotherapy, radiation, or combined‐modality treatment. Although the same doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapeutic regimen has been the mainstay of therapy over the last 30 years, risk‐adapted approaches have helped de‐escalate therapy in low‐risk patients while intensifying treatment for higher risk patients. Even patients who are not cured with initial therapy can often be salvaged with alternate chemotherapy combinations, the novel antibody‐drug conjugate brentuximab, or high‐dose autologous or allogeneic hematopoietic stem cell transplantation. The programmed death‐1 inhibitors nivolumab and pembrolizumab have both demonstrated high response rates and durable remissions in patients with relapsed/refractory HL. Alternate donor sources and reduced‐intensity conditioning have made allogeneic hematopoietic stem cell transplantation a viable option for more patients. Future research will look to integrate novel strategies into earlier lines of therapy to improve the HL cure rate and minimize long‐term treatment toxicities. CA Cancer J Clin 2018;68:116‐132. © 2017 American Cancer Society.

中文翻译:

霍奇金淋巴瘤:最近进展的回顾和更新

霍奇金淋巴瘤 (HL) 是一种独特的造血系统肿瘤,其特征是炎症背景中的癌性 Reed-Sternberg 细胞。患者通常在 20 多岁和 30 多岁时被诊断为 HL,并表现为膈上淋巴结肿大,通常伴有全身 B 症状。即使在晚期疾病中,HL 也可以通过联合化疗、放疗或联合治疗方式治愈。尽管相同的阿霉素、博来霉素、长春碱和达卡巴嗪化疗方案在过去 30 年中一直是治疗的中流砥柱,但适应风险的方法有助于降低低风险患者的治疗规模,同时加强对高风险患者的治疗。即使初始治疗未治愈的患者通常也可以通过替代化疗组合来挽救,新型抗体药物偶联物 brentuximab,或高剂量自体或同种异体造血干细胞移植。程序性死亡 1 抑制剂 nivolumab 和 pembrolizumab 在复发/难治性 HL 患者中均显示出高反应率和持久缓解。替代供体来源和降低强度的条件使异基因造血干细胞移植成为更多患者的可行选择。未来的研究将着眼于将新策略整合到早期治疗中,以提高 HL 治愈率并最大限度地减少长期治疗毒性。CA Cancer J Clin 2018;68:116-132。© 2017 美国癌症协会。程序性死亡 1 抑制剂 nivolumab 和 pembrolizumab 在复发/难治性 HL 患者中均显示出高反应率和持久缓解。替代供体来源和降低强度的条件使异基因造血干细胞移植成为更多患者的可行选择。未来的研究将着眼于将新策略整合到早期治疗中,以提高 HL 治愈率并最大限度地减少长期治疗毒性。CA Cancer J Clin 2018;68:116-132。© 2017 美国癌症协会。程序性死亡 1 抑制剂 nivolumab 和 pembrolizumab 在复发/难治性 HL 患者中均显示出高反应率和持久缓解。替代供体来源和降低强度的条件使异基因造血干细胞移植成为更多患者的可行选择。未来的研究将着眼于将新策略整合到早期治疗中,以提高 HL 治愈率并最大限度地减少长期治疗毒性。CA Cancer J Clin 2018;68:116-132。© 2017 美国癌症协会。未来的研究将着眼于将新策略整合到早期治疗中,以提高 HL 治愈率并最大限度地减少长期治疗毒性。CA Cancer J Clin 2018;68:116-132。© 2017 美国癌症协会。未来的研究将着眼于将新策略整合到早期治疗中,以提高 HL 治愈率并最大限度地减少长期治疗毒性。CA Cancer J Clin 2018;68:116-132。© 2017 美国癌症协会。
更新日期:2017-12-01
down
wechat
bug